Ivosidenib and Combination Chemotherapy

Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
25 patients (estimated)
Sponsors
Northwestern University
Collaborators
National Cancer Institute (NCI)
Tags
Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, MIDH2 Inhibitor, White Blood Cell Stimulant
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1756
NCT Identifier
NCT04250051

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.